Related Experiment Video
Updated: Feb 16, 2026

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice
Published on: April 3, 2011
The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse
Claudia M Wever1,2, Dominique Geoffrion2, Bruno M Grande3,4
1a Department of Medicine , McGill University, Lady Davis Institute, Jewish General Hospital , Montreal , Canada.
Abstract:
Relapse occurs in 10-40% of Burkitt lymphoma (BL) patients that have completed intensive chemotherapy regimens and is typically fatal. While treatment-naive BL has been characterized, the genomic landscape of BL at the time of relapse (rBL) has never been reported. Here, we present a genomic characterization of two rBL patients. The diagnostic samples had mutations common in BL, including MYC and CCND3. Additional mutations were detected at relapse, affecting important pathways such as NFκB (IKBKB) and MEK/ERK (NRAS) signaling, glutamine metabolism (SIRT4), and RNA processing (ZFP36L2). Genes implicated in drug resistance were also mutated at relapse (TP53, BAX, ALDH3A1, APAF1, FANCI). This concurrent genomic profiling of samples obtained at diagnosis and relapse has revealed mutations not previously reported in this disease. The patient-derived cell lines will be made available and, along with their detailed genetics, will be a valuable resource to examine the role of specific mutations in therapeutic resistance.
Related Concept Videos
Evolutionary Relationships through Genome Comparisons
Cell Lines
Genomics
Genome Size and the Evolution of New Genes
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...

